Salud financiera de hoja de balance de Precipio

Salud financiera controles de criterios 4/6

Precipio tiene un patrimonio de los accionistas total de $14.4M y una deuda total de $341.0K, lo que sitúa su ratio deuda-patrimonio en 2.4%. Sus activos y pasivos totales son $18.1M y $3.7M respectivamente.

Información clave

2.4%

Ratio deuda-patrimonio

US$341.00k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$1.50m
Patrimonio	US$14.43m
Total pasivo	US$3.67m
Activos totales	US$18.10m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Jun 12

Precipio shares surge on HemeScreen Anemia Panel launch

Jun 08

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

May 10

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

May 05

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

May 03

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($3.7M) de PRPO superan a sus pasivos a corto plazo ($3.1M).

Pasivo a largo plazo: Los activos a corto plazo de PRPO ($3.7M) superan a sus pasivos a largo plazo ($531.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: PRPO tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de PRPO ha pasado de 79.9% a 2.4% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: PRPO tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: PRPO tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 4.1% cada año.

Salud financiera de hoja de balance de Precipio

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Precipio Receives Noncompliance Letter from the Nasdaq

Recent updates

New major risk - Financial position

Precipio, Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: US$4.51 loss per share (vs US$10.73 loss in FY 2022)

Investors Holding Back On Precipio, Inc. (NASDAQ:PRPO)

Precipio, Inc. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

Precipio, Inc.'s (NASDAQ:PRPO) Subdued P/S Might Signal An Opportunity

Consensus revenue estimates increase by 11%

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Market cap size

New minor risk - Share price stability

Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings released: US$0.54 loss per share (vs US$0.40 loss in FY 2021)

Price target decreased to US$4.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Receives Noncompliance Letter from the Nasdaq

Precipio, Inc. Appoints Sharon Robins as its Senior Director of Laboratory & Hospital Sales for the Product’s Division

Precipio, Inc. Launches New 1-Step Technology for All Hemescreen Assays

Second quarter 2022 earnings released: US$0.094 loss per share (vs US$0.14 loss in 2Q 2021)

Precipio, Inc. Welcomes Toni-Ann Mills as its Senior Director for Learning & Development

Forecast to breakeven in 2023

Precipio to distribute HemeScreen through Fisher Healthcare channel

Precipio, Inc. Appoints Keith Meadors as Senior Vice President of its Products Division

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Precipio Signs First IV-Cell Customer Agreement

Price target decreased to US$4.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Precipio, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.20 loss in 2Q 2020)

Precipio terminates its equity line with Lincoln Park

We Think Some Shareholders May Hesitate To Increase Precipio, Inc.'s (NASDAQ:PRPO) CEO Compensation

Precipio, Inc. Launches Hemescreen® Anemia Panel, One-Of-Its-Kind Testing Tool

Precipio shares surge on HemeScreen Anemia Panel launch

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.78 loss in 1Q 2020)

Precipio, Inc. Launches New Hemescreen Panel for AML, with an Unparalleled 4-Hour Turnaround-Time

Precipio shares surge on launching hemescreen panel for Acute Myeloid Leukemia

Precipio: COVID-19 Testing At Amazon Is An Impressive Yet Transitory Fluke

Precipio, Inc. Launches Rapid COVID-19 Antibody Test on Amazon Platform

Precipio shares jump on launching its rapid COVID-19 antibody test on Amazon platform

Price target increased to US$7.00

Precipio, Inc. to Report Q4, 2020 Results on Mar 31, 2021

Precipio, Inc. Announces Board and Committee Changes

Precipio Launches COVID-19 Antibody Testing at Point-of-Care

Precipio Signs HemeScreen™ Deals with Two Leading Oncology Groups

Precipio, Inc. Signs Sales & Marketing Agreement for HemeScreen™ with Major Oncology Distributor

Precipio & ADS Biotec Launch Seven Beta Sites for IV-Cell™

Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Value Index

Precipio, Inc.(NasdaqCM:PRPO) dropped from Russell Microcap Index

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera